What does SEED Therapeutics do?

SEED Therapeutics, Inc. is a clinical-stage biotechnology company based in King of Prussia, PA, founded in 2019. The company specializes in developing molecular glue degraders aimed at targeting undruggable proteins associated with diseases such as cancer, neurodegeneration, immunology, and virology. SEED utilizes its proprietary RITE3™ platform, which combines structure-based drug design, computational chemistry, and chemical biology to enhance targeted protein degradation. The company's mission focuses on overcoming scientific challenges in discovering molecular glues for therapies that address debilitating diseases. SEED has a pipeline of nine programs, including its lead product, ST-01156, a brain-penetrant RBM39 degrader for Ewing sarcoma and other RBM39-dependent cancers, which is set to enter clinical trials. SEED collaborates with Eisai Co., Ltd. and has partnerships with Eli Lilly and BeyondSpring Pharmaceuticals to support its research and development efforts.